Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients

BACKGROUND: CD19 chimeric antigen receptor T (CAR-T) cells demonstrate remarkable remission rates in pediatric and adult patients with refractory or relapsed (r/r) acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL). In 2016, we initiated a clinical trial with in-house produced...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Immunother Cancer
Autores principales: Itzhaki, Orit, Jacoby, Elad, Nissani, Abraham, Levi, Michal, Nagler, Arnon, Kubi, Adva, Brezinger, Karin, Brayer, Hadar, Zeltzer, Li-at, Rozenbaum, Meir, Vernitsky, Helly, Markel, Gal, Toren, Amos, Avigdor, Abraham, Schachter, Jacob, Besser, Michal J
Formato: Artigo
Lenguaje:Inglês
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7061891/
https://ncbi.nlm.nih.gov/pubmed/32152221
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000148
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares